This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on ISI (2)  • Contact me when this article is cited  Related Content  • Similar articles in this journal

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

We read with interest the article on the neurologic manifestation of Wegener granulomatosis (WG) by de Groot et al,¹ which described a prospective series of 128 consecutive patients with WG ascertained between 1991 and 1997 who underwent a standardized neurologic evaluation, including history, examination, electroencephalography, and electrodiagnostic testing. The authors determined that 56 patients (44%) had a peripheral neuropathy: a distal symmetric polyneuropathy in 31 (55%) and multiple mononeuropathy in 25 (45%). Weakness was present in 19 patients with neuropathy (34%), and muscle atrophy occurred in 24 (43%), implying that the neuropathy was purely sensory in more than 50%. All patients were treated with immunosuppressive agents to induce remission (generally oral cyclophosphamide and corticosteroids). The authors reported that whereas patients with multiple mononeuropathy exhibited a significant improvement in disability after treatment, those with a symmetric polyneuropathy did not.

We suspect that this study overestimated the true incidence of vasculitic involvement . . . [Full Text of this Article]